News

Deal Announcements

Koronis Pharmaceuticals Closes $20 Million Series D

Friday, June 29, 2007 5:00:00 AM PDT | VentureDeal Staff
SEATTLE, WA --  Anti-viral company Koronis Pharmaceuticals announced that it has closed a fourth round of venture capital financing, receiving $20 million.

The company is developing anti-viral therapeutics that help treat patients afflicted with HIV infection.  Koronis is currently in Phase 2a proof-of-concept studies for a small molecule treatment that works through Viral Decay Acceleration principles.

The lead investor in the round was Pacific Horizon Ventures.  They were joined by return investor Asset Management Company.  The company intends to use the proceeds to advance its candidates through the drug trial process.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1